PTCT Ptc Therapeutics Inc

Price (delayed)

$40.37

Market cap

$2.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.37

Enterprise value

$3.27B

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
Ptc Therapeutics's revenue has increased by 32% YoY and by 6% from the previous quarter
PTCT's gross profit is up by 32% YoY and by 6% QoQ
Ptc Therapeutics's equity has shrunk by 131% YoY
The quick ratio has dropped by 65% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
71.34M
Market cap
$2.88B
Enterprise value
$3.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.74
Earnings
Revenue
$569.38M
EBIT
-$421.66M
EBITDA
-$337.33M
Free cash flow
-$280.44M
Per share
EPS
-$7.37
Free cash flow per share
-$3.94
Book value per share
-$1.27
Revenue per share
$8
TBVPS
$13.39
Balance sheet
Total assets
$1.8B
Total liabilities
$1.89B
Debt
$532.15M
Equity
-$90.58M
Working capital
$297.23M
Liquidity
Debt to equity
-5.87
Current ratio
1.62
Quick ratio
1.53
Net debt/EBITDA
-1.15
Margins
EBITDA margin
-59.2%
Gross margin
94.1%
Net margin
-91.7%
Operating margin
-65.9%
Efficiency
Return on assets
-26.8%
Return on equity
-983.2%
Return on invested capital
-39.8%
Return on capital employed
-31.9%
Return on sales
-74.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
1.08%
1 week
12.08%
1 month
33.01%
1 year
-3.93%
YTD
1.36%
QTD
8.2%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$569.38M
Gross profit
$536.02M
Operating income
-$375.12M
Net income
-$521.99M
Gross margin
94.1%
Net margin
-91.7%
PTCT's operating margin is up by 32% year-on-year and by 5% since the previous quarter
Ptc Therapeutics's revenue has increased by 32% YoY and by 6% from the previous quarter
PTCT's gross profit is up by 32% YoY and by 6% QoQ
The net income has contracted by 15% YoY

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.74
The EPS is down by 10% year-on-year
Ptc Therapeutics's equity has shrunk by 131% YoY
Ptc Therapeutics's revenue has increased by 32% YoY and by 6% from the previous quarter
The price to sales (P/S) is 30% lower than the 5-year quarterly average of 7.1 and 7% lower than the last 4 quarters average of 5.4

Efficiency

How efficient is Ptc Therapeutics business performance
The return on equity has dropped by 179% since the previous quarter
The ROIC has contracted by 30% YoY and by 11% from the previous quarter
Ptc Therapeutics's ROA has decreased by 18% YoY and by 3.9% from the previous quarter
The ROS is up by 9% year-on-year and by 8% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 4.8% less than the total liabilities
The quick ratio has dropped by 65% year-on-year and by 12% since the previous quarter
Ptc Therapeutics's current ratio has shrunk by 64% YoY and by 13% QoQ
Ptc Therapeutics's equity has shrunk by 131% YoY
PTCT's debt to equity has dropped by 102% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.